Phase I Study of Anakinra in Patients With Metastatic Cancer Expressing the Interleukin-1 Gene
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Related Information Registry Information
Alternate Title
Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene
Basic Trial Information
Phase | Type | Status | Age | Protocol IDs |
---|
Phase I | Treatment | Completed | 18 and over | NCI-03-C-0281 NCT00072111 |
Objectives Primary - Determine the maximum tolerated dose and dose-limiting toxicity of anakinra in patients with metastatic cancer expressing the interleukin-1 gene.
- Determine the steady state pharmacokinetics of this drug in these patients.
Secondary - Determine the antitumor efficacy of this drug in these patients.
- Determine gene expression changes in tumor biopsies and circulating leukocyte and cytokine levels in these patients before and after treatment with this drug.
Entry Criteria Disease Characteristics:
- Diagnosis of metastatic cancer
- Measurable disease
- Able to be percutaneously biopsied with minimum morbidity on protocol NCI-99-C-0128
- Tumor expression of interleukin-1 by biopsy
- Progressive disease during prior standard first-line chemotherapy OR refused standard first-line chemotherapy
- No active intracranial or leptomeningeal metastases
- Prior radiotherapy to or resection of intracranial metastatic disease allowed provided there is no evidence of active disease on MRI or CT scan for the past month AND there is no requirement for concurrent anticonvulsant or steroid medications
Prior/Concurrent Therapy:
Biologic therapy - More than 30 days since prior biologic therapy
- No concurrent systemic immune modulators
Chemotherapy - See Disease Characteristics
-
More than 30 days since prior chemotherapy
Endocrine therapy - See Disease Characteristics
-
No concurrent steroids
Radiotherapy - See Disease Characteristics
-
More than 14 days since prior localized radiotherapy to non-target lesions and recovered
- More than 30 days since other prior radiotherapy
Surgery - See Disease Characteristics
Other - At least 30 days since prior antibiotic therapy for infection
Patient Characteristics:
Age Performance status Life expectancy Hematopoietic - Platelet count greater than 75,000/mm3
-
Absolute neutrophil count greater than 1,500/mm3
Hepatic - PT within 2 seconds of the upper limit of normal
- Bilirubin less than 1.5 mg/dL
Renal - Creatinine no greater than 1.6 mg/dL
OR -
Creatinine clearance greater than 30 mL/min
Other - Not pregnant or nursing
-
Negative pregnancy test
- No allergy to proteins made from bacteria
- No active infection
-
HIV negative
Expected Enrollment A total of 3-24 patients will be accrued for this study within 1-2 years. Outline This is a dose-escalation study. Patients receive anakinra subcutaneously 1-3 times daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of anakinra until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6 patients are treated at that dose.
Trial Contact Information
Trial Lead Organizations NCI - Center for Cancer Research | | | Steven Libutti, MD, Principal investigator | | | |
Related Information PDQ® clinical trial NCI-99-C-0128
Registry Information | | Official Title | | Phase I Study of Anakinra Mediated Tumor Regression and Angiogenesis Inhibition in Subjects with Cancers Producing Interleukin-1 | | Trial Start Date | | 2003-09-17 | | Registered in ClinicalTrials.gov | | NCT00072111 | | Date Submitted to PDQ | | 2003-09-17 | | Information Last Verified | | 2006-04-01 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |